
In an interview at the recent Radiological Society of North America (RSNA) conference, Alex Pozdnyakov, M.D. discussed findings from a new meta-analysis, which revealed that prostate-specific membrane antigen/positron emission tomography (PSMA PET) imaging in patients with prostate cancer recurrence led to treatment changes that resulted in a pooled 60.2 percent rate of prostate cancer-free survival at 20 months.






























